- Identify new advances in imaging technology to properly diagnose patients with retinal diseases with less potential risk and better diagnostic acumen.
- Discuss the risks and benefits of the recently introduced therapies for neovascular age-related macular degeneration and identify which patients might potentially benefit from their use.
- Develop an understanding of the latest surgical options for retinal detachment and macular-hole repair, and the identification of patients who would benefit from which technique.
- Anita Agarwal; David Brown; Peter Campbell; Steve Charles; Emily Chew; Kimberly Drenser; Amani Fawzi; Mrinali Gupta, Deeba Husain; Joo Young Lee; Eric Nudleman, Kirk Packo, Kim Stepien; Akitaka Tsujikawa
- Bailey Freund: Allergan, Bayer, Genentech, Heidelberg Engineering, Novartis, Optovue, Zeiss [Consultant/Advisor (C)]; Genentech [Research Grant Support (R)]
- Brandon Lujan: Genentech/Roche, RegenxBio, Translational Imaging Innovations, Lineage Cell Therapeutics [Consultant/Advisor (C)]; Genentech/Roche [Research Grant Support (R)]
- Prithvi Mruthyunjaya: Castle Biosciences, Aura Biosciences [Consultant/Advisor (C)]
- Kourous Rezai: Alcon [Consultant/Advisor (C)]
- SriniVas Sadda: Optos, Heidelberg Engineering, Centervue, Novartis, Amgen, Allergan, Roche/Genentech, Merck, 4DMT [Consulant/Advisor (C)]; Carl Zeiss Meditec, Topcon, Nidek [Research Grant Support (R)]
- David Sarraf: Amgen, Bayer, Genentech, Heidelberg, Novartis, Optovue, Regeneron, Topcon [Consultant/Advisor (C), Research Grant Support (R)]
- Eliott Sohn: Dutch Ophthalmic [Consultant/Advisor (C)], Oxford BioMedica [Research Grant Support (R)]
- Charles Wykoff: Acucela, Adverum, Alimera Sciences, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside Biomedical, DORC, EyePoint, Genentech/Roche, Iveric Bio (formerly Ophthotech), Kodiak, Merck, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio, Santen, Takeda [Consultant/Advisor (C)]; Adverum, Aerie Pharmaceuticals, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, IONIS Pharmaceuticals, Iveric Bio (formerly Ophthotech), Kodiak, Neurotech, Novartis, Opthea, Optos, Outlook Therapeutics, Recens Medical, Regeneron, Regenxbio, Samsung, Santen, Xbrane Biopharma [Research Grant Support (R)]
- Susan Bressler: Bayer, Regeneron, Boehringer Ingelheim, Genentech Roche Biocon, Biogen, Mylan, Merck, Amgen, Notal Vision [Research Grant Support (R)]; Amgen [Other Chair Data and Safety Monitoring]; Boehringer Ingelheim [Other eye point]
- Karl Csaky: Roche/Genentech, Ocular Therapeutix [Consultant/Advisor (C)]
- Lloyd Aiello; Rajenda Apte; Peter Campochiaro; Antonio Capone; Paul Chan; Philip Ferrone; Gaurav Gaiha; Baker Hubbard; Christine Kay; Mark Pennesi; Schlomit Schaal; Adrienne Scott; Andrew Schachat; Lucia Sobrin
- Szilard Kiss: Adverum, Alcon, Optos, Regenxbio, Spark, Regeneron, Novartis, Genentech/Roche [Consultant/Advisor (C)], Adverum, Regenxbio, Fortress Bio [Equity Owner (O)]
- Jennifer Lim: Alcon, Allergan, Genentech/Roche, Novartis, Aura Biosciences, Quark, Ophthea, Santen [Consultant/Advisor (C)]; Genentech/Roche, Regeneron, Graybug, Stealth, Chegdu Pharmaceuticals [Research Grant Support (R)]
- Prithivi Mruthyunjaya: Castle Biosciences, Aura Biosciences [Consultant/Advisor (C)]
- Aaron Nagiel: Allergan Retina, Biogen, Regenxbio [Consultant/Advisor (C)]
- Dante Pieramici: Adverum, Allegro, Gemini, Genentech, Novartis, Regeneron, Regenx Bio [Consultant/Advisor (C)]; Adverum, Allergan, Apellis, Gemini, Genentech, Inc, Greybug, Ionis, Kodiac, Novartis, Regeneron, Regenx Bio, Stealth [Research Grant Support (R)]
- Jennifer Sun: Novo Nordisk, Novartis, Merck, Roche [travel support]; Novartis, Roche, Boehinger Ingelheim [Research Grant Support (R)]
- Cynthia Toth: Alcon, Hemosonics [Patents/Royalty (P)]; EMMES, Inc. [Consultant/Advisor (C)]
- David Zacks: ONL Therapeutics, Inc [Consultant/Advisor (C)]
- Thomas Aaberg; Alexander Brucker; Bernard Doft; Dean Eliott; Harry Flynn; Sunir Garg; Tarek Hassan; Jeffrey Heier; Mark Johnson; Peter Kaiser; Richard Kaiser; Alice Lyon; Darius Moshfeghi; Jose Pulido; Reginald Sanders; Gaurav Shah; Paul Sternberg; Lejla Vajzovic; George Williams; Steven Yeh
- David Boyer: Genentech, Regeneron, Roche, Bayer, Allergan, Novartis, Adverum, Regenexbio, Graybug, Ophthea, Allegro, Eye Point, Aerie, Oxiuron, DTx, Jcyte [Consultant/Advisor (C)]; Ophthea, Allegro, Aerie, Oxiuron, Jcyte [Research Grant Support (R)]
- Stanley Chang: Genentech [Consultant/Advisor (C)]
- David Chow: Alcon, Katalyst, DORC, Roche, Novartis, Bayer [Consultant/Advisor (C)]
- Donald D’Amico: Alcon, Inc., Iveric bio, Inc. [Consultant/Advisor (C)], Iveric bio, Inc. [Equity Owner (O)]
- Allen Ho: Notal [Consultant/Advisor (C)]
- Jason Hsu: Genentech/Roche, Regeneron, Novartis [Research Grant Support (R)]
- Judy Kim: Adverum, Allergan, Clearside, Genentech, Novartis, Notal Vision [Consultant/Advisor (C)]; Optos [Research Grant Support (R)]
- Joan Miller: KalVista Pharmaceuticals, ONL Therapeutics, Sunovion, Genentech/Roche [Consultant/Advisor (C)]; Valeant Pharmaceuticals, ONL Therapeutics, Drusolv Therapeutics [Patents/Royalty (P)]; ONL Therapeutics [Equity Owner (O)]; Lowy Medical Research Institute [Research Grant Support (R)]
- Edwin Ryan: Alcon Surgical [Consultant/Advisor (C), Patents/Royalty (P)]
- Trese: Retinal Solutions [Equity Owner (O), Patents/Royalty (P), Research Grant Support (R)]
- Lloyd Aiello; Jorge Arroyo; Andrew Antoszyk; Jeffrey Heier; Tara McCannel; William Mieler; Andrew Moshfeghi; David Parke; Adrienne Scott; Allison Shuren; Ivan Suner; James Vander; Keith Warren; Charles Pat Wilkinson
- Robert Avery: Adverum, Alimera, Allergan, Amgen, Apellis, Bausch & Lomb, Clearside, Eyepoint, Genentech, Helio Vision, InFocus Capital Partners, Iridex, Notal Vision, Novartis, Ocular Therapeutix, Pr3vent AI, RegenXbio, Replenish, Re-vana Therapeutics, Santen, Visionary Ventures [Consultant/Advisor (C); Adverum, Alcon, Bristol-Myers Squibb, Gilead Sciences, InFocus Capital Partners, Novartis, Regeneron, Replenish, Visionary Ventures [Equity Owner (O)]; Genentech [Research Grant Support (R)]; Replenish [Patents/Royalty (P)]
- Mark Blumenkranz: Verana Health [Equity Owner (O)]
- Neil Bressler: Bayer, Biogen, Novartis, Regeneron, Roche (Genentech), Samsung Bioepis [Research Grant Support (R)]
- Julia Haller: Bristol-Myers Squibb, Celgene [Other Board of Directors]; Aura Bioscience, Kalvista, Lowy Medical Research Institute, Bionic Sight LLC [Consultant/Advisor (C)]
- Allen Ho: Notal [Consultant/Advisor (C)]
- Peter Hovland: Castle Biosciences [Consultant/Advisor (C)]
- Mark Humayun: Alcon Laboratories, Allergan, Intellimicro, Lutronic Vision, Outlook Therapeutics, Regenerative Patch Technologies, Replenish, Santen, Inc. [Consultant/Advisor (C)]; Alcon Laboratories Inc., Santen, Inc. [Other Lecture Fees]; Allergan [Other Speaker/Honorarium]; Lutronic Vision, Outlook Therapeutics, Regenerative Patch Technologies, Replenish, Intellimicro (GEB) [Equity Owner (O)]; Intellimicro (GEB), IRIDEX, Regenerative Patch Technologies, Replenish, Second Sight Medical Products, Inc. [Patents/Royalty (P)]
- Ivana Kim: Novartis, Kodiak Sciences, Castle Biosciences, Biophytis [Consultant/Advisor (C)]; Allergan [Research Grant Support (R)]
- Philip Rosenfeld: Regeneron, Carl Zeiss Meditec [Consultant/Advisor (C)], Carl Zeiss Meditec [Research Grant Support (R)]
- Jennifer Sun: Novo Nordisk, Novartis, Merck, Roche [travel support]; Novartis, Roche, Boehinger Ingelheim [Research Grant Support (R)]
- VEGF Blockage Prevents Health Retinal Tissue Regrowth in Retinal Vascular Disease
- Assessing the Frequency and Duration of Post-Injection Discomfort in Patients Receiving Anti-VEGF Injections: A Quality Improvement Project
- Effect of Vitrectomy and Panretinal Photocoagulation Versus Intravitreous Afilbercept on Visual Acuity in Patients with Vitreous Hemorrhage from Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
CME Information
Claim CME Credit
VR 24/7 | https://tinyurl.com/VR247
Available August 1, 2020 through October 31, 2020
Please view all 24/7 videos of interest before completing the evaluation and claiming CME credit.
VR Live | https://tinyurl.com/VRlive
Available September 22, 2020 through October 31, 2020
The VR Live evaluation and credit claim form for all live shows will be available beginning at 9:30 p.m. Eastern Time on September 22.
Objectives
At the conclusion of this activity, learners should be able to:
CME Accreditation and Credit Designation*
In support of improving patient care, this activity has been planned and implemented by Beaumont Health and The Retina Society. Beaumont Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
VR 24/7 | Beaumont Health designates this enduring material for a maximum of 22.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
VR LIVE | Beaumont Health designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
*Number of credits subject to change
Disclosure of Conflicts of Interest
Planning Committee Disclosures
Antonio Capone, Jr., MD: Consultant/Advisor for Novartis AG, Ohr Pharmaceuticals, Spark Therapeutics, ProQR Therapeutics; Research Grant Support from Aura Biosciences, Genentech, Ionis Pharmaceuticals; Stock Ownership with Broadspot; and Intellectual Property Rights/Patent Holder for Phoenix Technology Group, Retinal Solutions.
Bernard Doft, MD: No relevant financial relationships with commercial interests to disclose.
Jeffrey Heier, MD: No relevant financial relationships with commercial interests to disclose.
Allen Ho, MD: Consultant/Advisor for Alcon, Allergan, Chengdu Kang Hong, Genentech, Regeneron, Rebenxbio
Jennifer Lim, MD: Consultant/Advisor for Genentech, Alcon, Ophtheal, Quark, AllerganAura Biosciences, Novartis AG, and Santen; Research Grant Support from Chegdu Pharmaceuticals, Regeneron, Graybug, Stealth
Cynthia Toth, MD: Intellectual Property Rights/Patent Holder for Alcon, Hemosonics; Consultant/Advisor for EMMES
David Zacks, MD, PhD: Consultant/Advisor for ONL Therapeutics
Presenter Disclosures: Refer to the opening slide of each presentation for presenter disclosure information.
Panelist/Moderator Disclosures
Show 1: August 25, 2020
The following panelists/moderators have no relevant financial relationships with commercial interests to disclose:
The following panelists/moderators have identified relevant financial relationships with commercial interests:
Show 2: September 8, 2020
The following panelists/moderators have no relevant financial relationships with commercial interests to disclose:
The following panelists/moderators have identified relevant financial relationships with commercial interests:
Disclosures Pending as of 7/30/2020: Thomas Lee
Show 3: September 21, 2020
The following panelists/moderators have no relevant financial relationships with commercial interests to disclose:
The following panelists/moderators have identified relevant financial relationships with commercial interests:
Show 4: September 22, 2020
The following panelists/moderators have no relevant financial relationships with commercial interests to disclose:
The following panelists/moderators have identified the following relevant financial relationships with commercial interests:
Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, Beaumont Health implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
Unapproved Use: It is the policy of Beaumont Health to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.
The following 24/7 presentations are not eligible for CME credit:
CME Questions? cme@beaumont.edu